INSTRUCTIONS Hypertrophic cardiomyopathy: New hope for an old disease
- Read the article. The test for this CE activity is to be taken online at www.nursingcenter.com/CE/nursing.
- You'll need to create (it's free!) and log in to your personal CE Planner account before taking online tests. Your planner will keep track of all your Lippincott Professional Development online CE activities for you.
- There's only one correct answer for each question. A passing score for this test is 13 correct answers. If you pass, you can print your certificate of earned contact hours and access the answer key. If you fail, you have the option of taking the test again at no additional cost.
- For questions, contact Lippincott Professional Development: 1-800-787-8985.
- Registration deadline is September 3, 2021.
Lippincott Professional Development will award 1.0 contact hour for this continuing nursing education activity. Lippincott Professional Development is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749 for 1.0 contact hour, and the District of Columbia, Georgia, and Florida CE Broker #50-1223.
Payment: The registration fee for this test is $12.95.
Hypertrophic cardiomyopathy: New hope for an old disease
GENERAL PURPOSE: To review and update information about HCM. LEARNING OBJECTIVES/OUTCOMES: After completing this continuing-education activity, you should be able to: 1. Explain the pathophysiology of HCM. 2. List the clinical manifestations of HCM. 3. Plan appropriate nursing interventions for patients with HCM.
- The primary structural abnormality in HCM is thickening of the wall of the
- right atrium.
- left ventricle.
- right ventricle.
- A common pathophysiologic characteristic of HCM is
- tricuspid valve regurgitation.
- infective endocarditis.
- diastolic dysfunction.
- SAM of the mitral valve leaflet is generally the direct cause of
- LVOT obstruction.
- ventricular septal hypertrophy.
- myocyte disarray.
- The treatment of choice for patients who have HCM with symptomatic AF is
- surgical septal myectomy.
- pharmacologic cardioversion.
- synchronized electrical cardioversion.
- Which statement about the angina that accompanies HCM is correct?
- It is often atypical.
- It always involves epicardial arterial stenosis.
- It does not occur at rest.
- A clinical manifestation of HCM that usually occurs in later stages of the disease is
- fluid retention.
- peripheral neuropathy.
- Which of the following ECG abnormalities is common with HCM?
- prolonged PR interval
- T wave inversion
- tall R waves
- Which test is performed routinely to determine HCM's severity?
- contrast-enhanced CMR
- continuous ambulatory ECG monitoring
- transthoracic echocardiography
- A risk factor for SCD in patients who have HCM is
- unexplained syncope.
- a history of atrial tachycardia.
- LV hypertrophy of at least 15 mm.
- Which of the following is indicated for patients with HCM who are at highest risk for SCD?
- biventricular pacemaker
- implantable loop recorder
- Which of the following can help minimize dysrhythmias and allow better ventricular filling in patients with HCM?
- What percentage of patients with HCM progress to the burn-out stage of the disease?
- 2% to 3%
- 12% to 13%
- 20% to 30%
- Which of the following is a Class Ia agent that depresses sodium-dependent depolarization?
- Which of the following interventions for HCM remodels the affected area by creating a localized myocardial infarction?
- mitral valvuloplasty
- surgical septal myectomy
- Which term refers to a person's individual sequence of genes?
- For patients with HCM, which of the following drugs is contraindicated?
- Patients who have HCM should avoid taking which type of drugs?
- Nurses should inform patients who have HCM to do all of the following except
- take nitroglycerine for angina.
- stay hydrated.
- monitor for sudden weight gain.